| Link from antibiotic to EUCAST MIC-distributions |
Breakpoints
|
Entero- bacteriaceae |
Pseudo- monas |
Acineto- bacter |
Staphylo- coccus |
Entero- coccus |
Streptococcus A,B,C,G |
S.pneu- moniae |
Other strepto cocci |
H.influenzae | M.catarrhalis | P.multocida |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Method: | -- | A | A | A | A | B | B | B | B | B | B | B |
| Penicillin G+ | 0.25/2 | -- | -- | -- | 0.12/0.12 | IE | 0.25/0.25* |
0.06/2 Meningitis: 0.06/0.06 |
0.25/2 | IE | -- | IE |
| Penicillin V+ | IE | -- | -- | -- | Note | -- | Note | Note | Note | -- | -- | 0.5/0.5 |
|
Oxacillin+ (Cloxa-, dicloxa- & flucloxacilin) |
IE | -- | -- | -- | Note | -- | Note | Note | -- | -- | -- | -- |
| Cefoxitin | -- | -- | -- | -- | 4/4 | -- | -- | -- | -- | -- | -- | -- |
|
Ampicillin+ (Amoxicillin) |
2/8 | 1/8 | -- | -- | Note | 4/8 | Note | 0.5/2 | 0.5/2 | 1/1 | Note | 0.5/0.5 |
| Amoxicillin-clavulanate+ | 2/8 | 1/8 | -- | -- | Note | 4/8 | Note | Note | Note | 1/1 | 1/1 | IE |
| Pivmecillinam+(U) | IE | 8/8 | -- | -- | Note | -- | -- | -- | -- | -- | -- | -- |
|
Piperacillin- tazobactam+ |
4/16 | 8/16 | 16/16 | IE | Note | Note | Note | Note | Note | Note | Note | IE |
| Imipenem+ | 2/8 | 2/8a | 4/8 | 2/8 | Note | 4/8 | 2/2* | 2/2* | 2/2 | 2/2 | 2/2 | IE |
| Meropenem+ | 2/8 | 2/8 | 2/8 | 2/8 | Note | -- | 2/2* | 2/2* Meningitis: 0.25/1 |
2/2 | 2/2 Meningitis: 0.25/1 |
2/2 | IE |
| Ertapenem+ | 0.5/1 | 0.5/1 | -- | -- | Note | -- | 0.5/0.5* | 0.5/0.5 | 0.5/0.5 | 0.5/0.5 | 0.5/0.5 | IE |
| Aztreonam+ | 4/8 | 1/8 | 1/16 | -- | -- | -- | -- | -- | -- | IE | IE | IE |
| Link from antibiotic to EUCAST MIC-distributions |
Breakpoints
|
Entero- bacteriaceae |
Pseudo- monas |
Acineto- bacter |
Staphylo- coccus |
Entero- coccus |
Streptococcus A,B,C,G |
S.pneu- moniae |
Other strepto cocci |
H.influenzae | M.catarrhalis | P.multocida |
| Cefalothin | 1/8 | 1/8 | -- | -- | Note | -- | 0.5/1 | 0.25/1 | -- | -- | -- | -- |
| Cefalexin | 1/8 | 1/8 | -- | -- | Note | -- | 1/1 | 1/1 | -- | -- | -- | -- |
| Cefadroxil | 1/8 | 1/8 | -- | -- | Note | -- | 1/1 | 1/1 | -- | -- | IE | -- |
| Loracarbef | 2/4 | 2/4 | -- | -- | Note | -- | 1/1 | 1/1 | -- | 2/4 | 2/4 | -- |
| Cefuroxime-axetil | 2/2 | -- | -- | -- | Note | -- | 0.12/2 | 0.12/0.25 | -- | 2/2 | 2/2 | -- |
| Cefpodoxime | 1/2 | 1/2 | -- | -- | Note | -- | 0.06/1 | 0.06/0.12 | -- | 0.25/0.5 | 1/2 | IE |
| Ceftibuten | 1/4 | 1/4 | -- | -- | -- | -- | 1/4 | -- | -- | 0.25/0.5 | 1/4 | IE |
| Cefuroxime+ | 4/8 | 8/8b | -- | -- | Note | -- | 0.5/0.5 | 0.5/1 | Pending | 1/2 | 1/2 | IE |
| Cefotaxime+ | 1/2 | 1/2 | -- | -- | Note | -- | 0.5/0.5 | 0.5/2 | Pending | 0.12/0.12 | 0.12/0.12 | 0.12/1 |
| Ceftriaxone+ | 1/2 | 1/2 | -- | -- | Note | -- | 0.5/0.5 | 0.5/2 | Pending | 0.12/0.12 | 0.12/0.12 | 0.12/1 |
| Ceftazidime+ | 4/8 | 1/8 | 8/8 | -- | -- | -- | -- | -- | -- | -- | -- | IE |
| Cefepime+ | 4/8 | 1/8 | 8/8 | -- | Note | -- | 0.5/0.5 | 1/2 | Pending | 0.25/0.25 | 0.25/0.25 | IE |
| Cefixime | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Oral cephalosporins - harmonisation by EUCAST early 2009.
aProteus
and Morganella species are considered poor targets for imipenem and
testing should be avoided.
bCefuroxime
Enterobacteriaceae breakpoints are valid for Escherichia coli, Klebsiella spp
and Proteus mirabilis in infections originating in the urinary tract and for a dosage of 1.5 g x 3 or
more.
|
*Isolat med MIC-värden över S/I-brytpunkten är
ovanliga eller har ännu inte beskrivits. Identifiering och
resistensbestämning skall upprepas och om resultatet konfirmeras skickas
isolatet till referenslaboratorium. (U) Brytpunkterna gäller endast vid nedre okomplicerad urinvägsinfektion. |
*Isolates with MIC values above the S/I-breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory.. (U) = Breakpoints valid for uncomplicated urinary tract infections only. |
|
Note/brytpunkt i hypertext - länk till särskild information om brytpunkten. Informationen finns i samma dokument som den länk som ges från artnamnen. För den som skriver ut tabellen på papper är det viktigt att även alla fotnoter skrivs ut och följer med tabellen. |
Note/breakpoint in hypertext = a link to a footnote. If you print the table on paper, remember to print the footnotes - they contain important information on methodology. |
| 4/8 - sättet att beskriva
MIC-gränser (exempelvis 4/8) skall tolkas S<
4 och R>8
mg/L. IE - Klinisk effekt utesluts ej men in vitro och/eller in vivo dokumentation saknas. -- RAF avråder från resistensbestämning. Ej relevant behandlingsalternativ:
|
4/8 - breakpoints
for SIR-categorisation: S< 4 mg/l and
R>8 mg/L. IE - Clinical effect is not ruled out but EUCAST/SRGA have not been able to find enough clinical evidence to determine a breakpoint. -- SRGA advices against susceptibility testing. Not a relevant alternative:
|
|
Metod: A = grundmedium utan tillsatser. Inkubation 35o C i luft. B = grundmedium + 5% skakhästblod.+ NAD. Inkubation i 5 % CO2 vid 35o C . |
Method: A = medium without additives. Incubation in air, 35o C. B = medium + 5% defibrinated horse blood + NAD. Incubation in 5 % CO2 at 35o C. |
